Close Menu

Brain Cancer

News and reporting on brain cancer.

Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.

Using 26 pediatric ependymoma patient samples, researchers sequenced 18,500 single cells to classify and analyze discrete neoplastic subpopulations.

By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.

Investigators reported that methylation profiling could distinguish brain cancer subtypes and could detect kidney cancer with striking sensitivity in early experiments.

In Nature this week: population sequencing led to rare disease diagnoses, analysis of marine green alga leads to discovery of new phylum, and more.

The Irish Times' Karlin Lillington writes that Ireland needs a national public genome program.

Researchers analyzed evolutionarily constrained non-coding mutations in genome sequences from dozens of glioblastoma patients, identifying regulation-related changes.

Launched in 2016 by researchers in Utah, the firm recently published a genome-wide signature that predicts survival of glioblastoma patients. 

Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.

A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.